女性不妊症の世界市場レポート 2025年

女性不妊症の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.1％で21億9,000万米ドルに成長します。予測期間中の成長は、不妊問題に対する意識の高まり、多嚢胞性卵巣症候群の症例の増加、子宮異常の増加、遺伝性疾患の発生率の増加、肥満の増加など、いくつかの要因に起因すると考えられます。この期間に予想される主な動向としては、着床前遺伝子検査の進歩、技術革新、新規診断技術、妊孕性温存技術、遠隔医療の台頭などが挙げられます。

不妊症の有病率の増加は、今後数年間の女性不妊症市場の拡大を促進すると予想されます。不妊症とは、避妊せずに性交渉を12カ月間定期的に行っても妊娠できない状態を指します。不妊症の増加は、出産の遅れ、ライフスタイルの変化、環境毒素、肥満率の増加、ストレスレベルの上昇などの要因に影響されています。女性不妊症の治療は、不妊を妨げる根本的な医学的、ホルモン的、または構造的な問題に対処・管理し、妊娠の可能性を高め、永久的な不妊を防ぐために必要です。例えば、2024年7月、英国の公的機関であるHuman Fertilization and Embryology Authority（英国保健社会福祉省傘下）は、英国の認可不妊治療クリニックが2022年に5万2,500人の患者に対して約77,000回の新鮮胚移植および凍結胚移植体外受精を実施したと報告しました。これらの患者の90％以上がパートナーと一緒に治療を受けており、約10万人が関与しています。その結果、不妊症の有病率の上昇が女性不妊症市場の成長を牽引しています。

女性不妊症市場の主な企業は、競争優位性を獲得するために、非侵襲的診断検査などの革新的製品の開発に注力しています。非侵襲的診断検査とは、手術や体への浸透を必要とせずに状態や疾患を検出する医療検査です。例えば、米国に本社を置くバイオテクノロジー企業Heranova Lifesciences社は2024年8月、子宮内膜症用の非侵襲的診断検査HerResolveの早期アクセスプログラムを導入しました。子宮内膜症は世界中で約2億人の女性が罹患しており、不妊、痛み、出血などの症状を引き起こしています。多くの女性にとって、正確な診断には症状の発現から平均7～10年を要します。これは、症状が多様であることと、最も信頼性の高い診断方法である腹腔鏡下手術に侵襲的な処置が必要であることが主な原因です。HerResolveは、この診断の遅れを数年から数ヶ月に短縮し、患者とヘルスケアの転帰を改善する可能性を秘めています。HerResolveの目標は、このタイムラインを大幅に短縮し、患者のケアと結果を向上させることです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界女性不妊症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の女性不妊症市場：成長率分析
• 世界の女性不妊症市場の実績：規模と成長, 2019-2024
• 世界の女性不妊症市場の予測：規模と成長, 2024-2029, 2034F
• 世界女性不妊症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の女性不妊症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロミフェンクエン酸塩
• ゴナドトロピン
• メトホルミン
• レトロゾール
• ブロモクリプチン
• 世界の女性不妊症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の女性不妊症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の女性不妊症市場クロミフェンクエン酸塩のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口クロミフェンクエン酸塩
• 注射用クロミフェンクエン酸塩
• 世界の女性不妊症市場ゴナドトロピンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えゴナドトロピン
• 尿中ゴナドトロピン
• ヒト絨毛性ゴナドトロピン（hCG）
• 世界の女性不妊症市場メトホルミンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放性メトホルミン
• 徐放性メトホルミン
• 世界の女性不妊症市場レトロゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口レトロゾール錠
• 注射用レトロゾール
• 世界の女性不妊症市場ブロモクリプチンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ブロモクリプチン錠
• 鼻腔内ブロモクリプチン

第7章 地域別・国別分析

• 世界の女性不妊症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の女性不妊症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 女性不妊症市場：競合情勢
• 女性不妊症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• Abbott Laboratories
• Mayo Clinic
• Teva Pharmaceutical Industries Ltd
• Commonwealth Serum Laboratories Ltd
• Organon Theramex
• Juniper Reproductive Health Ltd.
• Sumitomo Pharma
• Ferring Pharmaceuticals
• Livzon Pharmaceutical Group Co.
• Mankind Pharma
• Kissei Pharmaceutical Co Ltd
• ASKA Pharmaceutical Co. Ltd.
• Fuji Pharma Co. Ltd.
• ARMC IVF

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 女性不妊症市場2029：新たな機会を提供する国
• 女性不妊症市場2029：新たな機会を提供するセグメント
• 女性不妊症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to sustain a pregnancy. It is a multifactorial condition that results from various factors affecting the reproductive system.

The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is commonly prescribed to stimulate ovulation in women with infertility. It can be administered in various forms, such as oral, parenteral, and others, and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The female infertility market research report is one of a series of new reports from The Business Research Company that provides female infertility market statistics, including female infertility industry global market size, regional shares, competitors with a female infertility market share, detailed female infertility market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. This female infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The female infertility market size has grown steadily in recent years. It will grow from $1.79 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be attributed to several factors, including the growing trend of women delaying childbirth, changes in lifestyle, increased government initiatives, a rising aging population, and the growing use of assisted reproductive technology (ART) treatments.

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth during the forecast period can be attributed to several factors, including rising awareness of fertility issues, an increase in cases of polycystic ovary syndrome, a growing number of uterine abnormalities, a higher incidence of genetic disorders, and increasing obesity. Key trends expected during this period include advancements in preimplantation genetic testing, technological innovations, novel diagnostic technologies, fertility preservation techniques, and the rise of telemedicine.

The growing prevalence of infertility is expected to fuel the expansion of the female infertility market in the coming years. Infertility is defined as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The rise in infertility is influenced by factors such as delayed childbearing, lifestyle changes, environmental toxins, increasing obesity rates, and higher stress levels. Treatment for female infertility is necessary to address and manage the underlying medical, hormonal, or structural issues that hinder fertility, improving the chances of conception and preventing permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based public body under the Department of Health and Social Care, reported that licensed fertility clinics in the UK conducted nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. More than 90% of these patients received treatment with a partner, involving around 100,000 individuals. As a result, the rising prevalence of infertility is driving the growth of the female infertility market.

Key companies in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive advantage. A non-invasive diagnostic test is a medical examination that detects conditions or diseases without the need for surgery or penetration of the body. For example, in August 2024, Heranova Lifesciences, a biotech company based in the US, introduced an early access program for HerResolve, a non-invasive diagnostic test designed for endometriosis. Endometriosis affects around 200 million women globally, causing symptoms such as infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7 to 10 years from the onset of symptoms, largely due to the diverse nature of symptoms and the invasive procedure required for the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve has the potential to reduce this diagnostic delay from years to months, improving patient and healthcare outcomes. The goal of HerResolve is to significantly shorten this timeline, enhancing patient care and results.

In April 2023, CCRM Fertility, a network of fertility clinics based in the US, acquired the New Hope Center for Reproductive Medicine for an undisclosed amount. This acquisition allows CCRM to expand its fertility services on the East Coast, providing greater access to high-quality fertility care, advanced testing, state-of-the-art laboratories, and in-house genetics and research, all contributing to leading success rates. The New Hope Center for Reproductive Medicine, also based in the US, is a fertility clinic offering a variety of services, including in vitro fertilization (IVF) to address female infertility.

Major players in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd.

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in female infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the female infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Female Infertility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on female infertility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for female infertility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The female infertility market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate
• 2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)
• 3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
• 4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole
• 5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck And Co. Inc; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Female Infertility Market Characteristics

3. Female Infertility Market Trends And Strategies

4. Female Infertility Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Female Infertility Growth Analysis And Strategic Analysis Framework

• 5.1. Global Female Infertility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Female Infertility Market Growth Rate Analysis
• 5.4. Global Female Infertility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Female Infertility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Female Infertility Total Addressable Market (TAM)

6. Female Infertility Market Segmentation

• 6.1. Global Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clomiphene Citrate
• Gonadotropins
• Metformin
• Letrozole
• Bromocriptine
• 6.2. Global Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.3. Global Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Female Infertility Market, Sub-Segmentation Of Clomiphene Citrate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Clomiphene Citrate
• Injectable Clomiphene Citrate
• 6.5. Global Female Infertility Market, Sub-Segmentation Of Gonadotropins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Gonadotropins
• Urinary Gonadotropins
• Human Chorionic Gonadotropin (hCG)
• 6.6. Global Female Infertility Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Metformin
• Extended-Release Metformin
• 6.7. Global Female Infertility Market, Sub-Segmentation Of Letrozole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Letrozole Tablets
• Injectable Letrozole
• 6.8. Global Female Infertility Market, Sub-Segmentation Of Bromocriptine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Bromocriptine Tablets
• Intranasal Bromocriptine

7. Female Infertility Market Regional And Country Analysis

• 7.1. Global Female Infertility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Female Infertility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Female Infertility Market

• 8.1. Asia-Pacific Female Infertility Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Female Infertility Market

• 9.1. China Female Infertility Market Overview
• 9.2. China Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Female Infertility Market

• 10.1. India Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Female Infertility Market

• 11.1. Japan Female Infertility Market Overview
• 11.2. Japan Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Female Infertility Market

• 12.1. Australia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Female Infertility Market

• 13.1. Indonesia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Female Infertility Market

• 14.1. South Korea Female Infertility Market Overview
• 14.2. South Korea Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Female Infertility Market

• 15.1. Western Europe Female Infertility Market Overview
• 15.2. Western Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Female Infertility Market

• 16.1. UK Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Female Infertility Market

• 17.1. Germany Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Female Infertility Market

• 18.1. France Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Female Infertility Market

• 19.1. Italy Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Female Infertility Market

• 20.1. Spain Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Female Infertility Market

• 21.1. Eastern Europe Female Infertility Market Overview
• 21.2. Eastern Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Female Infertility Market

• 22.1. Russia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Female Infertility Market

• 23.1. North America Female Infertility Market Overview
• 23.2. North America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Female Infertility Market

• 24.1. USA Female Infertility Market Overview
• 24.2. USA Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Female Infertility Market

• 25.1. Canada Female Infertility Market Overview
• 25.2. Canada Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Female Infertility Market

• 26.1. South America Female Infertility Market Overview
• 26.2. South America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Female Infertility Market

• 27.1. Brazil Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Female Infertility Market

• 28.1. Middle East Female Infertility Market Overview
• 28.2. Middle East Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Female Infertility Market

• 29.1. Africa Female Infertility Market Overview
• 29.2. Africa Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Female Infertility Market Competitive Landscape And Company Profiles

• 30.1. Female Infertility Market Competitive Landscape
• 30.2. Female Infertility Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Female Infertility Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Abbott Laboratories
• 31.3. Mayo Clinic
• 31.4. Teva Pharmaceutical Industries Ltd
• 31.5. Commonwealth Serum Laboratories Ltd
• 31.6. Organon Theramex
• 31.7. Juniper Reproductive Health Ltd.
• 31.8. Sumitomo Pharma
• 31.9. Ferring Pharmaceuticals
• 31.10. Livzon Pharmaceutical Group Co.
• 31.11. Mankind Pharma
• 31.12. Kissei Pharmaceutical Co Ltd
• 31.13. ASKA Pharmaceutical Co. Ltd.
• 31.14. Fuji Pharma Co. Ltd.
• 31.15. ARMC IVF

32. Global Female Infertility Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Female Infertility Market

34. Recent Developments In The Female Infertility Market

35. Female Infertility Market High Potential Countries, Segments and Strategies

• 35.1 Female Infertility Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Female Infertility Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Female Infertility Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer